Adrenocortical secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{CMG}}; | |||
{{CMG}}; ☃↵ | |||
==Overview== | ==Overview== | ||
==Adrenocortical carcinoma secondary prevention== | ==Adrenocortical carcinoma secondary prevention== | ||
Patients should be followed at 3-month intervals after initial treatment for 2 to 3 years. | * Patients should be followed at 3-month intervals after initial treatment for 2 to 3 years. | ||
Surveillance intervals may be increased to 6 months for the next 5 years. | |||
Surveillance should also include: | * Surveillance intervals may be increased to 6 months for the next 5 years. | ||
Cross-sectional imaging | |||
The use | * Surveillance should also include: | ||
Laboratory evaluation | ** [[Cross-sectional]] [[imaging]] of [[chest]], [[abdomen]], and [[pelvis]] | ||
Evaluation of side effects is also important in case | ** The use of [[FDG-PET]] for [[lesions]] of an unclear nature | ||
** Laboratory evaluation for [[steroid hormones]] | |||
** Evaluation of side effects is also important in case of [[adjuvant]] [[mitotane]] [[therapy]] | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 16:52, 3 October 2017
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; ☃↵
Overview
Adrenocortical carcinoma secondary prevention
- Patients should be followed at 3-month intervals after initial treatment for 2 to 3 years.
- Surveillance intervals may be increased to 6 months for the next 5 years.
- Surveillance should also include: